Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 61 articles:
HTML format
Text format



Single Articles


    July 2017
  1. XIAO W, Zheng J, Zhou B, Pan L, et al
    Replication Protein A 3 Is Associated with Hepatocellular Carcinoma Tumorigenesis and Poor Patient Survival.
    Dig Dis. 2017 Jul 7. doi: 10.1159/000478977.
    PubMed     Text format     Abstract available


  2. LABENZ C, Prenosil V, Koch S, Huber Y, et al
    Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Dig Dis. 2017 Jul 4. doi: 10.1159/000477578.
    PubMed     Text format     Abstract available


    March 2017
  3. DI PASCOLI M, Ceranto E, De Nardi P, Donato D, et al
    Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report.
    Dig Dis. 2017 Mar 1. doi: 10.1159/000458722.
    PubMed     Text format     Abstract available


    January 2017
  4. KEPPLER D
    Progress in the Molecular Characterization of Hepatobiliary Transporters.
    Dig Dis. 2017;35:197-202.
    PubMed     Text format     Abstract available


  5. HAUSSINGER D, Kordes C
    Mechanisms of Tauroursodeoxycholate-Mediated Hepatoprotection.
    Dig Dis. 2017;35:224-231.
    PubMed     Text format     Abstract available


  6. ALVAREZ-SOLA G, Uriarte I, Latasa MU, Urtasun R, et al
    Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis.
    Dig Dis. 2017;35:158-165.
    PubMed     Text format     Abstract available


  7. PERUGORRIA MJ, Labiano I, Esparza-Baquer A, Marzioni M, et al
    Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
    Dig Dis. 2017;35:275-281.
    PubMed     Text format     Abstract available


  8. LARUSSO NF, Tabibian JH, O'Hara SP
    Role of the Intestinal Microbiome in Cholestatic Liver Disease.
    Dig Dis. 2017;35:166-168.
    PubMed     Text format     Abstract available


  9. REICH M, Klindt C, Deutschmann K, Spomer L, et al
    Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage.
    Dig Dis. 2017;35:235-240.
    PubMed     Text format     Abstract available


  10. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    PubMed     Text format     Abstract available


  11. STEINACHER D, Claudel T, Trauner M
    Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2017;35:282-287.
    PubMed     Text format     Abstract available


  12. HALILBASIC E, Steinacher D, Trauner M
    Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
    Dig Dis. 2017;35:288-292.
    PubMed     Text format     Abstract available


  13. PALLEN MJ, Quraishi MN
    The Gut Microbiota and the Hepatologist: Will Our Bugs Prove to be the Missing Link?
    Dig Dis. 2017;35:377-383.
    PubMed     Text format     Abstract available


  14. GALLE PR
    Treating Hepatobiliary Cancers: The Oncology Way.
    Dig Dis. 2017;35:384-386.
    PubMed     Text format     Abstract available


  15. POSE E, Cardenas A
    Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Dig Dis. 2017;35:402-410.
    PubMed     Text format     Abstract available


  16. DUFFY AG, Greten TF
    Treating Hepatobiliary Cancer: The Immunologic Approach.
    Dig Dis. 2017;35:390-396.
    PubMed     Text format     Abstract available


    June 2016
  17. FITZ JG
    Hepatology after Hepatitis C.
    Dig Dis. 2016;34:603-606.
    PubMed     Text format     Abstract available


  18. DIAZ-GONZALEZ A, Reig M, Bruix J
    Treatment of Hepatocellular Carcinoma.
    Dig Dis. 2016;34:597-602.
    PubMed     Text format     Abstract available


  19. HALILBASIC E, Fuchs C, Traussnigg S, Trauner M, et al
    Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.
    Dig Dis. 2016;34:580-588.
    PubMed     Text format     Abstract available


    January 2016
  20. HOGDALL D, O'Rourke CJ, Taranta A, Oliveira DV, et al
    Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma.
    Dig Dis. 2016;34:440-51.
    PubMed     Text format     Abstract available


  21. SCHMIDT N, Thimme R
    Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma.
    Dig Dis. 2016;34:429-37.
    PubMed     Text format     Abstract available


  22. GERBES AL
    Liver Cirrhosis and Kidney.
    Dig Dis. 2016;34:387-90.
    PubMed     Text format     Abstract available


  23. GARCIA-TSAO G
    Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis.
    Dig Dis. 2016;34:382-6.
    PubMed     Text format     Abstract available


  24. SAFFIOTI F, Pinzani M
    Development and Regression of Cirrhosis.
    Dig Dis. 2016;34:374-81.
    PubMed     Text format     Abstract available


  25. ZOLLER H, Henninger B
    Pathogenesis, Diagnosis and Treatment of Hemochromatosis.
    Dig Dis. 2016;34:364-73.
    PubMed     Text format     Abstract available


  26. JAHN D, Rau M, Wohlfahrt J, Hermanns HM, et al
    Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies.
    Dig Dis. 2016;34:356-63.
    PubMed     Text format     Abstract available


  27. THIMME R
    Highlights from Hepatology 2015: From Chronic Hepatitis to Hepatocellular Carcinoma.
    Dig Dis. 2016;34:I-II.
    PubMed     Text format    


  28. KUDO M
    Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors.
    Dig Dis. 2016;34:714-730.
    PubMed     Text format     Abstract available


  29. NISHIDA N, Kudo M
    Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations.
    Dig Dis. 2016;34:708-713.
    PubMed     Text format     Abstract available


  30. NAGAI T, Arao T, Nishio K, Matsumoto K, et al
    Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma.
    Dig Dis. 2016;34:702-707.
    PubMed     Text format     Abstract available


  31. OGAWA C, Minami Y, Morita M, Noda T, et al
    Prediction of Embolization Area after Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using SYNAPSE VINCENT.
    Dig Dis. 2016;34:696-701.
    PubMed     Text format     Abstract available


  32. KAWASAKI T, Hata KY, Kinoshita D, Takayama M, et al
    Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
    Dig Dis. 2016;34:692-695.
    PubMed     Text format     Abstract available


  33. IWAMOTO T, Imai Y, Kogita S, Igura T, et al
    Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma.
    Dig Dis. 2016;34:679-686.
    PubMed     Text format     Abstract available


  34. ARIZUMI T, Ueshima K, Iwanishi M, Minami T, et al
    Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.
    Dig Dis. 2016;34:671-678.
    PubMed     Text format     Abstract available


  35. CHISHINA H, Hagiwara S, Nishida N, Ueshima K, et al
    Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Dig Dis. 2016;34:659-664.
    PubMed     Text format     Abstract available


  36. YADA N, Sakurai T, Minami T, Arizumi T, et al
    Prospective Risk Analysis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C by Ultrasound Strain Elastography.
    Dig Dis. 2016;34:650-653.
    PubMed     Text format     Abstract available


  37. SCORLETTI E, Byrne CD
    Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Dig Dis. 2016;34 Suppl 1:11-8.
    PubMed     Text format     Abstract available


  38. MAZZOTTI A, Caletti MT, Sasdelli AS, Brodosi L, et al
    Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction.
    Dig Dis. 2016;34 Suppl 1:3-10.
    PubMed     Text format     Abstract available


  39. MAHLI A, Hellerbrand C
    Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:32-9.
    PubMed     Text format     Abstract available


  40. SCHERER A, Dufour JF
    Treatment of Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:27-31.
    PubMed     Text format     Abstract available


  41. DE ALWIS NM, Anstee QM, Day CP
    How to Diagnose Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:19-26.
    PubMed     Text format     Abstract available


  42. MINAMI Y, Minami T, Chishina H, Kono M, et al
    US-US Fusion Imaging in Radiofrequency Ablation for Liver Metastases.
    Dig Dis. 2016;34:687-691.
    PubMed     Text format     Abstract available


  43. TAKITA M, Iwanishi M, Minami T, Kono M, et al
    Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease.
    Dig Dis. 2016;34:654-658.
    PubMed     Text format     Abstract available


  44. GALLE PR
    Extended Abstract: Management of Liver Cancer.
    Dig Dis. 2016;34:438-9.
    PubMed     Text format     Abstract available


  45. WEISKIRCHEN R, Tacke F
    Liver Fibrosis: From Pathogenesis to Novel Therapies.
    Dig Dis. 2016;34:410-22.
    PubMed     Text format     Abstract available


  46. LAMMERT F
    Genetics in Common Liver Diseases: From Pathophysiology to Precise Treatment.
    Dig Dis. 2016;34:391-5.
    PubMed     Text format     Abstract available


  47. CHAZOUILLERES O
    Novel Aspects in the Management of Cholestatic Liver Diseases.
    Dig Dis. 2016;34:340-6.
    PubMed     Text format     Abstract available


  48. KOYAMA Y, Xu J, Liu X, Brenner DA, et al
    New Developments on the Treatment of Liver Fibrosis.
    Dig Dis. 2016;34:589-96.
    PubMed     Text format     Abstract available


    January 2015
  49. PARES A
    Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
    Dig Dis. 2015;33 Suppl 2:125-33.
    PubMed     Text format     Abstract available


  50. HERKEL J
    Regulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases.
    Dig Dis. 2015;33 Suppl 2:70-4.
    PubMed     Text format     Abstract available


  51. JOPSON L, Jones DE
    Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management.
    Dig Dis. 2015;33 Suppl 2:109-14.
    PubMed     Text format     Abstract available


  52. CORRIGAN M, Hirschfield GM
    Aspects of the Pathophysiology of Primary Biliary Cirrhosis.
    Dig Dis. 2015;33 Suppl 2:102-8.
    PubMed     Text format     Abstract available


  53. KOHLI R, Myronovych A, Tan BK, Salazar-Gonzalez RM, et al
    Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
    Dig Dis. 2015;33:440-6.
    PubMed     Text format     Abstract available


  54. TRAUNER M, Halilbasic E, Claudel T, Steinacher D, et al
    Potential of nor -Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
    Dig Dis. 2015;33:433-9.
    PubMed     Text format     Abstract available


  55. SANYAL AJ
    Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
    Dig Dis. 2015;33:426-32.
    PubMed     Text format     Abstract available


  56. MASYUK TV, Masyuk AI, LaRusso NF
    TGR5 in the Cholangiociliopathies.
    Dig Dis. 2015;33:420-5.
    PubMed     Text format     Abstract available


  57. ZIMMER V, Liebe R, Lammert F
    Nuclear receptor variants in liver disease.
    Dig Dis. 2015;33:415-9.
    PubMed     Text format     Abstract available


  58. KRONES E, Wagner M, Eller K, Rosenkranz AR, et al
    Bile Acid-induced cholemic nephropathy.
    Dig Dis. 2015;33:367-75.
    PubMed     Text format     Abstract available


  59. ABU-HAYYEH S, Williamson C
    Progesterone metabolites as farnesoid X receptor inhibitors.
    Dig Dis. 2015;33:300-6.
    PubMed     Text format     Abstract available


  60. VAN BUUREN HR, Lammers WJ, Harms MH, Hansen BE, et al
    Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:118-24.
    PubMed     Text format     Abstract available


  61. POUPON R
    Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:115-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: